Elanco Animal Health CFO Robert VanHimbergen Acquires Deferred Stock Units in July 2026 Transaction

Executive Compensation Transaction at Elanco Animal Health

The disclosure filed by Elanco Animal Health on July 28, 2026, details a beneficial ownership change involving the company's CFO. Robert M. VanHimbergen, who serves as Executive Vice President and Chief Financial Officer, executed a transaction on July 24, 2026, acquiring deferred stock units as part of the company's executive compensation structure. This type of transaction is routinely reported to the Securities and Exchange Commission under Section 16(a) of the Securities Exchange Act of 1934, which requires company officers and directors to disclose changes in their beneficial ownership of company securities.

Deferred stock units represent a form of equity compensation that allows executives to defer receipt of company stock or its cash equivalent until a future date or upon termination of employment. The units acquired by VanHimbergen in this transaction are governed by Elanco's Executive Deferral and Stock Match Plan, which establishes the terms and conditions for settlement. This compensation structure is common among large publicly traded companies seeking to align executive interests with shareholder returns while providing flexibility in tax and cash flow management.

Details of the Deferred Stock Unit Acquisition

VanHimbergen acquired exactly 7.9093 deferred stock units in the July 24, 2026 transaction. Each deferred stock unit carries the economic equivalent of one share of Elanco common stock. The company's disclosure indicates that these units are held in direct beneficial ownership form, meaning VanHimbergen has direct control and interest in the units rather than holding them through an intermediary or trust arrangement. The filing provides specificity regarding the nature and settlement mechanics of the acquired units, which is relevant to investors seeking to understand executive compensation and stock ownership patterns at the company.

Following completion of this transaction, VanHimbergen's total direct beneficial ownership of deferred stock units reached 124.6979 units. This cumulative position reflects both the newly acquired units and previously held units under the same compensation plan. The precise decimal figures reported in the disclosure indicate that fractional units are permitted under Elanco's Executive Deferral and Stock Match Plan, likely resulting from dividend reinvestment provisions or other plan features that generate partial unit increments over time.

Settlement and Payout Provisions for Deferred Stock Units

According to the filing, deferred stock units held by VanHimbergen will settle in either cash or shares of Elanco common stock, with settlement timing dependent on termination of his employment or during specified future years as determined by the Executive Deferral and Stock Match Plan documents. This flexibility in settlement mechanism allows the company to manage its cash position while providing executives with security regarding the ultimate realization of their deferred compensation. Investors monitoring executive compensation practices may view such provisions as relevant to understanding potential future equity dilution or cash obligations.

The settlement provisions create a contingent economic interest in company stock that is separate from the executive's other compensation arrangements. Rather than receiving immediate stock grants, the deferral structure allows executives like VanHimbergen to accumulate units over time, with eventual conversion to shares or cash equivalents. This approach can have tax planning benefits for executives while also potentially encouraging longer-term employment tenure, as settlement dates may be structured to incentivize continued service with the company.

VanHimbergen's Role at Elanco Animal Health

Robert M. VanHimbergen holds the position of Executive Vice President and Chief Financial Officer at Elanco Animal Health, making him a senior executive with primary responsibility for the company's financial management, accounting, reporting, and treasury functions. As CFO, VanHimbergen is classified as an officer under SEC reporting rules and therefore subject to the insider disclosure requirements reflected in this Form 4 filing. His position as a senior financial executive at a publicly traded company places him among the individuals whose trading activity and beneficial ownership changes are monitored by investors and market participants as indicators of management confidence in the company.

The CFO role carries significant influence over strategic capital allocation decisions, financial planning, and investor relations communications. VanHimbergen's compensation structure, which includes deferred stock units alongside other likely forms of equity and cash compensation, reflects typical executive incentive arrangements designed to align his financial interests with those of Elanco shareholders. The continued acquisition of deferred stock units suggests ongoing participation in the company's equity compensation program as part of his total remuneration package.

Beneficial Ownership Reporting Requirements and Compliance

The disclosure was filed by Amy C. Seidel, serving as attorney-in-fact on behalf of VanHimbergen, and was executed on July 28, 2026, four days after the underlying transaction date. This filing represents compliance with SEC regulations requiring officers to report changes in beneficial ownership within specified timeframes. The form indicates that VanHimbergen is an officer of Elanco Animal Health but is not a director or 10 percent owner of the company, clarifying his specific relationship to the issuer for purposes of insider trading rules and reporting thresholds.

The disclosure document carries standard SEC language regarding the criminal penalties for intentional misstatements or omissions, underscoring the legal significance of accurate beneficial ownership reporting. Investors and market participants rely on these filings to obtain reliable information about the equity interests and compensation patterns of company insiders. The detailed reporting of transaction codes, security types, and ownership forms provides transparency regarding how executives' financial interests in the company are structured and evolve over time.

Equity Compensation Within the Animal Health Industry

Elanco Animal Health operates in the animal health and nutrition sector, a regulated industry requiring significant research and development investment, manufacturing capability, and regulatory compliance expertise. Within this industry, equity compensation programs for senior executives are standard practice, used to attract and retain experienced management talent while aligning executive incentives with shareholder value creation. Deferred stock unit arrangements provide flexibility that appeals to executives seeking tax-efficient compensation structures and companies seeking to manage equity dilution and cash flow considerations simultaneously.

The use of deferred units rather than immediate stock grants reflects contemporary trends in executive compensation design, wherein many large corporations have shifted toward more flexible, deferred equity arrangements. These structures can provide executives with greater control over the timing of taxable events while allowing companies to maintain compensation competitiveness in competitive talent markets. For Elanco, the use of such arrangements with senior financial officers like VanHimbergen demonstrates a structured approach to executive compensation governance and planning.

Tracking Executive Stock Ownership Changes

Investors monitoring executive compensation and insider ownership at Elanco Animal Health can access Form 4 filings through the SEC's EDGAR database to track beneficial ownership changes among company officers and directors. These filings provide a public record of insider transactions, compensation equity grants, and ownership positions, allowing investors to assess the level of insider confidence in the company and the incentive alignment between management and shareholders. The accumulation of deferred stock units by the CFO may be observed as one indicator among many regarding management's financial stake in the company's long-term performance.

The pattern of deferred stock unit acquisitions over time can reveal whether executives are consistently participating in equity compensation programs or whether participation varies with company performance or other factors. Investors may view consistent insider equity accumulation as a positive signal regarding management's confidence in the company's direction, though Form 4 filings alone do not provide complete information regarding executive decision-making motivations or market outlook. The systematic nature of equity compensation programs, where grants may occur at specified intervals, means that individual transactions should be evaluated within the context of the broader compensation plan structure.

Implications for Shareholder and Investor Considerations

The acquisition of deferred stock units by VanHimbergen represents compensation awarded within the existing Executive Deferral and Stock Match Plan framework, a mechanism through which Elanco manages executive incentive compensation. For shareholders, the existence and terms of such plans are material to understanding the company's equity structure, potential dilution from shares reserved for executive compensation, and the incentive alignment between management and owner interests. The deferred settlement feature adds a layer of complexity to equity compensation analysis, as it separates the grant date from the settlement date when actual shares are issued or cash is paid.

The filing does not indicate whether the deferred stock units were awarded as part of an annual bonus program, long-term incentive plan, or other specific compensation mechanism. However, the regularity of such acquisitions among senior executives at public companies suggests systematic compensation program operation rather than discretionary grants. Investors evaluating Elanco's corporate governance and executive compensation practices may wish to review the company's proxy statement and compensation committee disclosures for additional context regarding the design, performance metrics, and vesting conditions applicable to the Executive Deferral and Stock Match Plan.